This article was originally published in Start Up
Executive SummaryCoGenesys has licensed rights to albumin fusion proteins that improve the bioavailability of proteins better than other methods such as PEGylation, its founders believe. The start-up's pipeline presently contains a version of BNP for treating heart failure.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.